Sertralinum

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

**Sertralinum**
Natura chemica


Formula chemica	C ₁₇H ₁₇Cl ₂N
Massa molaris	306.229 g/mol
PubChem	68617
DrugBank	DB01104
Natura pharmacologica
Codex ATC	N06AB06 (WHO)
Tempus semivitae biologicum	~23–26 h
Metabolismus	iecore (hepaticus): CYP2B6
Metabolitus	Desmethylo-sertralinum
Excretio	renibus
Ad usum therapeuticum
Applicatio	per os
MedlinePlus	a697048 (Anglice)

Sertralinum est substantia psychoanaleptica, antidepressiva et inhibitor reabsorptionis serotonini selectivus. Quae ad conturbationem obsessionem-compulsionem et phobias curandas adhibetur.

Historia[recensere | fontem recensere]

Anno 1978 chemicus Willard Welsh societatis Pfizer mixturam Sertralini et enantiomerium eius fecit^[1]^[2]. Intra unum mensem Welsh enantiomeres inactivos removit, ut Sertralinum primus inhibitor reabsorptionis Serotonini selectivus purus fuerit. Anno 1991 Sertralinum in mercatum introductum est.

Natura Sertralini[recensere | fontem recensere]

Natura chemica[recensere | fontem recensere]

Sertralinum est naphtylaminum cuius structura chemica (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-aminum et massa molaris 306.229 g/mol est. Codex ATC est N06AB06.

Natura pharmacologica[recensere | fontem recensere]

Pharmacodynamica[recensere | fontem recensere]

Sertralinum imprimis inhibitor reabsorptionis serotonini affinitate sui notate cum transportatro serotonini (SERT) est, K_i = 2.0 habens^[3]. Novem mg/die sufficit ut transportatrorum dimidium serotonini impediatur^[4].

Pharmacocinetica[recensere | fontem recensere]

Tempus semivitae biologicum $t_{\frac {1}{2}}$ est circa 25 horae.^[5] Sertralinum substratum cytochromatum, imprimis CYP2B6, minor CYP3A4 et CYP2C19, est^[6]. Excretio est per urinas.

Usus Sertralini[recensere | fontem recensere]

Toxicitas[recensere | fontem recensere]

Dosis letalis ^[7] 2800-7000 mg/kg homini (mus: 336) est.

Effectus usu[recensere | fontem recensere]

Reactiones adversae[recensere | fontem recensere]

Conferatur pagina principalis Adversa drogae reactio.

Hyponatraemia^[8]

Nexus interni

Notae[recensere | fontem recensere]

↑ Willard M. Welch (1995). Discovery and preclinical development of the serotonin reuptake inhibitor sertraline. Advances in Medicinal Chemistry 3: 113-148
↑ JJ Li (2009). Triumph of the heart. The Story of Statins. Oxford University Press. Pag. 135
↑ http://www.abcam.com/Sertraline-hydrochloride-ab141068.pdf
↑ Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psych 161 (5): 826–35
↑ Fons.
↑ Obach R. S., Cox L. M., Tremaine L. M. (2005). "Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study". Drug Metab Dispos 33 (2): 262-70
↑ Shinkei Seishin Yakuri (1997). Neuropsychopharmacology. Bd. 19, S. 395
↑ Varela Piñón M., Adán-Manes J. (2017). "Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives". Clinical neuropharmacology 40 (4): 177-9

[1] Willard M. Welch (1995). Discovery and preclinical development of the serotonin reuptake inhibitor sertraline. Advances in Medicinal Chemistry 3: 113-148

[2] JJ Li (2009). Triumph of the heart. The Story of Statins. Oxford University Press. Pag. 135

[3] ttp://www.abcam.com/Sertraline-hydrochloride-ab141068.pdf

[4] Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psych 161 (5): 826–35

[5] Fons.

[6] Obach R. S., Cox L. M., Tremaine L. M. (2005). "Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study". Drug Metab Dispos 33 (2): 262-70

[7] Shinkei Seishin Yakuri (1997). Neuropsychopharmacology. Bd. 19, S. 395

[8] Varela Piñón M., Adán-Manes J. (2017). "Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives". Clinical neuropharmacology 40 (4): 177-9

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]